Výsledky vyhledávání - "E. Leitersdorf"

Akademický článek

Molecular genetics of cerebrotendinous xanthomatosis in Jews of north African origin.

Autor: A Reshef, V Meiner, V M Berginer, E Leitersdorf

Publikováno v: Journal of Lipid Research, Vol 35, Iss 3, Pp 478-483 (1994)

Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive sterol storage disease characterized by the accumulation of a bile alcohol, cholestanol, in diverse tissues. The disorder is manifested by extensive nervous system involvement, juvenile c

Externí odkaz: https://doaj.org/article/01914c29fb164f84b821a15253bb5c6b

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Identification and properties of the proline664-leucine mutant LDL receptor in South Africans of Indian origin.

Autor: DC Rubinsztein, GA Coetzee, AD Marais, E Leitersdorf, HC Seftel, DR van der Westhuyzen

Publikováno v: Journal of Lipid Research, Vol 33, Iss 11, Pp 1647-1655 (1992)

The incidence of familial hypercholesterolemia (FH) is high among South African Indians. The proline664-leucine low density lipoprotein (LDL)-receptor mutation was detected in four apparently unrelated Indian FH families in South Africa. This mutatio

Externí odkaz: https://doaj.org/article/49dfdfefa5c54f72a534e50f1461be9f

Zobrazit plný text záznamu

Akademický článek

Diverse effect of ethnicity on plasma lipoprotein[a] levels in heterozygote patients with familial hypercholesterolemia.

Autor: E Leitersdorf, Y Friedlander, JM Bard, JC Fruchart, S Eisenberg, Y Stein

Publikováno v: Journal of Lipid Research, Vol 32, Iss 9, Pp 1513-1519 (1991)

Plasma lipids, lipoproteins, and lipoprotein[a] (Lp[a]) levels were determined in 216 members of 14 families with familial hypercholesterolemia (FH). Ninety-nine subjects harbored a mutant low density lipoprotein (LDL) receptor allele as confirmed by

Externí odkaz: https://doaj.org/article/ec9ab24e38f34f7babc7384ecc30d799

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

‘Danger’ effect of low-density lipoprotein (LDL) and oxidized LDL on human immature dendritic cells

Autor: R. Zaguri, Dror Mevorach, Uriel Trahtemberg, Inna Verbovetski, Alon Krispin, Efrat Nahari, Mizhir Atallah, E. Leitersdorf

Publikováno v: Clinical and Experimental Immunology. 149:543-552

Summary Dendritic cell (DC) maturation may accelerate autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, and may contribute to accelerated atherosclerosis seen in these patients. The immune system responds to both exog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f87a15f18e0e610fda20056747431baf
https://doi.org/10.1111/j.1365-2249.2007.03444.x

Zobrazit plný text záznamu

The Rationale for Using HMG-CoA Reductase Inhibitors (‘Statins’) in Peripheral Arterial Disease

Autor: G. Erez, E. Leitersdorf

Publikováno v: European Journal of Vascular and Endovascular Surgery. 33:192-201

Atherosclerosis is a systemic process, and the leading cause of morbidity and mortality in the developed world. HMG-CoA reductase inhibitors (‘statins’) are potent lipid lowering drugs, which have been shown to reduce morbidity and mortality in p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c19d35e3aa1ac2da92e809447afb0be9
https://doi.org/10.1016/j.ejvs.2006.11.020

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management

Autor: E. Leitersdorf

Publikováno v: European Heart Journal Supplements. 3:E17-E23

International guidelines specify target concentrations of low-density lipoprotein cholesterol (LDL-C) to reduce the risk of coronary heart disease. Although statins are the most widely prescribed cholesterol-lowering drugs, they have a number of limi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e1756727661f38fe67c355a7b1360c2f
https://doi.org/10.1016/s1520-765x(01)90108-7

Zobrazit plný text záznamu

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

Autor: Eliot A. Brinton, Uma Kher, Sukrut Shah, Christopher P. Cannon, Michael Davidson, Antonio M. Gotto, Tanya B. Ashraf, Christine McCrary Sisk, Hayes Dansky, Yale Mitchel, Philip Barter, M. Gerstman, L. Howes, K. Kostner, P. Nestel, D. Sullivan, H. Brath, J. Patsch, B. Paulweber, H. Toplak, C.M. Constance, E. Howlett, D. Mymin, L. Pliamm, K.K. Saunders, J.-C. Tardif, R. Tytus, P. Aschner, S. Keinänen-Klukaanniemi, T. Strandberg, M.-R. Taskinen, G. Luc, D. Richter, J.L. Schlienger, Y. Zaïr, K.-F. Appel, M. Baar, C. Luley, U. Overhoff, T. Pomykaj, T. Schaefer, S.T. Lau, K.L.F. Lee, K. Tan, B. Tomlinson, M.W. Tsang, K. Badacsonyi, Á. Kalina, N. Kanakaridisz, L. Márk, É. Péterfai, L. Regos, I. Reiber, J. Takács, A. Vértes, A. Elis, D. Gavish, D. Harats, O. Hussein, T. Hayek, E. Leitersdorf, A.K. Bin Abdul Ghapar, K.H. Chee, S.B. Ismail, K.H. Ling, G.R.L. Ramanathan, K.H. Sim, R. Alvarado, M. Benavides, G.E. Cardona, G. Gonzalez, J. Verdejo, D.C.G. Basart, B.P.M. Imholz, J.J.C. Jonker, P.R. Nierop, J.L. Posma, Th.B. Twickler, E. Barrington-Ward, R. Cutfield, D.H. Friedlander, R.S. Scott, H. Istad, G. Langslet, G.K. Skjelvan, S.J. Campodónico Hoyos, R. Coloma Araniya, A. Gallegos C., C.A. Pino Morales, L. Watanabe, G.P. Arutyunov, A.B. Blokhin, M.G. Bubnova, S.Y. Marcevich, C. Álvarez Sánchez, L.A. Álvarez-Sala Walther, B. Gil Extremera, F. Perez Jimenez, L. de Teresa Parreño, C.-P. Anderberg, U. Hedin, A. Hellberg, P. Höök, T. Kjellström, P. Nilsson, A.G. Olsson, U. Rosenqvist, K. Tolagen, T. Wolff, A. Baskin, H.E. Bays, R.I. Bernstein, N. Bittar, E.A. Brinton, L.H.K. Chee, R.A. Cottiero, R.D. D'Agostino, M.H. Davidson, P.S. Denker, R.K. Garcia, R.K. Hippert, T. Isakov, S.R. Kaster, B. Kerzner, E.J. Klein, M.J. Koren, M.E. Kutner, D. Liljenquist, D.G. Lorch, R. Lorraine, B.C. Lubin, N.M. Lunde, T.J. Majchrzak, J.M. McKenney, S. Mukherjee, D.D. Muse, M.S. Otruba, J.E. Pappas, K. Patrick, S.J. Powell, E. Riffer, L.D. Rink, J.L. Rohlf, J.B. Rosen, P.D. Rosenbilt, E.M. Roth, C.J. Rubenstein, J. Rubino, L.A. Rudolph, A. Schneider, W.G. Short, J.C. Silverfield, D.P. Suresh, G.A. Tarshis, P.D. Toth, R.W. Townsend, T.O. Wahl

Publikováno v: Journal of clinical lipidology

Background In the Determining the Efficacy and Tolerability of cholesteryl ester transfer protein (CETP) INhibition with AnacEtrapib (DEFINE) trial, anacetrapib added to statin produced robust low-density lipoprotein cholesterol (LDL-C)-lowering and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed0c778769d9b9d7a78e7c69d7f43bd3
https://pubmed.ncbi.nlm.nih.gov/25670362

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání